Calyxt to merge with Cibus Global in all-stock deal; Q4 revenue nominal, cash $3.5M

Cibus, Inc.

Merger with Cibus Global: all-stock, Calyxt shareholders to own ~5% of combined company; expected close Q2 2023.
Cash and cash equivalents $3.5M as of Dec 31, 2022; cash runway through Q2 2023 with interim Cibus funding.
Revenue nominal in Q4 2022 vs $1.9M in Q4 2021 due to wind-down of soybean product line.
Total operating expenses $3.4M in Q4 2022 vs $6.6M in Q4 2021, driven by cost reduction actions.
Settlement with technology vendor: received $750K in Q4 2022 and another $750K in Q1 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Cibus, Inc. reported financial results for the fourth quarter ended December 31, 2022.

Period: the fourth quarter ended December 31, 2022
Result: reported results

Exact text from the filing

Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, today announced operating and financial results for its fourth quarter ended December 31, 2022.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Cibus, Inc. reported financial results for the year ended December 31, 2022.

Period: the year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 2, 2023, Calyxt, Inc. (the “Company”) announced its financial results for the year ended December 31, 2022.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Cibus, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-058307

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.